Market Closed -
Other stock markets
|
After market 02:23:23 pm | |||
94.15 EUR | -1.00% | 94.08 | -0.08% |
06:22pm | BioMérieux: FDA clearance for Vidas TBI test | CF |
May. 23 | BioMérieux, Pfizer to Collaborate on Antimicrobial Resistance Initiative in Malawi | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The company is in a robust financial situation considering its net cash and margin position.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Weaknesses
- With a 2024 P/E ratio at 24.6 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-6.41% | 12.2B | B+ | ||
-4.07% | 8.22B | B- | ||
+5.77% | 5.72B | B | ||
+27.52% | 5.42B | C | ||
-59.94% | 2.7B | D+ | ||
+8.04% | 2.63B | - | - | |
-6.47% | 2.38B | B- | ||
+21.79% | 2.1B | C | ||
-8.15% | 1.81B | D+ | ||
+0.97% | 1.57B | C |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- BIM Stock
- Ratings bioMérieux